StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$3.14−0.06 (-1.88%)

Close on Nov 17, 2026Market cap $53.94MP/E –Yield –

Verrica Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Verrica Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$13.35M. For fiscal 2025 it was -$17.63M. The highest annual figure on record is -$4.58M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.63M–
FY2024Dec 31, 2024-$60.93M–
FY2023Dec 31, 2023-$38.58M–
FY2022Dec 31, 2022-$18.65M–
FY2021Dec 31, 2021-$27.58M–
FY2020Dec 31, 2020-$30.21M–
FY2019Dec 31, 2019-$27.41M–
FY2018Dec 31, 2018-$17.87M–
FY2017Dec 31, 2017-$4.58M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.28M–
Q1 FY2026Mar 31, 2026-$9.16M–
Q4 FY2025Dec 31, 2025-$4.59M–
Q3 FY2025Sep 30, 2025$9.69M–
Q2 FY2025Jun 30, 2025-$10.04M–
Q1 FY2025Mar 31, 2025-$12.68M–
Q4 FY2024Dec 31, 2024-$16.06M–
Q3 FY2024Sep 30, 2024-$8.56M–
Q2 FY2024Jun 30, 2024-$16.36M–
Q1 FY2024Mar 31, 2024-$19.95M–
Q4 FY2023Dec 31, 2023-$14.51M–
Q3 FY2023Sep 30, 2023-$14.81M-911.6%
Q2 FY2023Jun 30, 2023-$4.67M–
Q1 FY2023Mar 31, 2023-$4.59M–
Q4 FY2022Dec 31, 2022-$4.95M–
Q3 FY2022Sep 30, 2022$1.83M–
Q2 FY2022Jun 30, 2022-$7.18M-387.4%
Q1 FY2022Mar 31, 2022-$8.34M–
Q4 FY2021Dec 31, 2021-$8.70M–
Q3 FY2021Sep 30, 2021-$10.60M–
Q2 FY2021Jun 30, 2021$2.50M–
Q1 FY2021Mar 31, 2021-$10.79M–
Q4 FY2020Dec 31, 2020-$6.10M–
Q3 FY2020Sep 30, 2020-$7.61M–
Q2 FY2020Jun 30, 2020-$8.59M–
Q1 FY2020Mar 31, 2020-$7.91M–
Q4 FY2019Dec 31, 2019-$8.21M–
Q3 FY2019Sep 30, 2019-$7.23M–
Q2 FY2019Jun 30, 2019-$5.05M–
Q1 FY2019Mar 31, 2019-$6.92M–
Q4 FY2018Dec 31, 2018-$6.90M–
Q3 FY2018Sep 30, 2018-$5.14M–
Q2 FY2018Jun 30, 2018-$3.68M–
Q1 FY2018Mar 31, 2018-$2.15M–
Q4 FY2017Dec 31, 2017-$1.85M–
Q3 FY2017Sep 30, 2017-$1.08M–

More Verrica Pharmaceuticals figures

See a number that looks wrong?